The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
about
A review of escitalopram and citalopram in child and adolescent depressionComparison of the enantiomers of (+/-)-doxanthrine, a high efficacy full dopamine D(1) receptor agonist, and a reversal of enantioselectivity at D(1) versus alpha(2C) adrenergic receptorsThe pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopramIn vivo steady-state pharmacokinetic outcome following clinical and toxic doses of racemic citalopram to ratsChronic treatment with escitalopram but not R-citalopram translocates Galpha(s) from lipid raft domains and potentiates adenylyl cyclase: a 5-hydroxytryptamine transporter-independent action of this antidepressant compoundPharmacological blockade of 5-HT7 receptors as a putative fast acting antidepressant strategySynthesis, fluorine-18 radiolabeling, and biological evaluation of N-((E)-4-fluorobut-2-en-1-yl)-2beta-carbomethoxy-3beta-(4'-halophenyl)nortropanes: candidate radioligands for in vivo imaging of the brain dopamine transporter with positron emissionCitalopram in the treatment of depression and other potential uses in psychiatry.Open-label treatment with citalopram in patients with irritable bowel syndrome: a pilot study.Serotonergic/glutamatergic interactions: potentiation of phencyclidine-induced stimulus control by citalopram.Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteersCitalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.Escitalopram--translating molecular properties into clinical benefit: reviewing the evidence in major depression.Escitalopram Versus Citalopram and Sertraline: A Double-Blind Controlled, Multi-centric Trial in Indian Patients with Unipolar Major Depression.Citalopram: a comprehensive review.Stereoisomers in Psychiatry: The Case of Escitalopram.Escitalopram.Enantiomeric antidepressant drugs should be considered on individual merit.Mutational mapping and modeling of the binding site for (S)-citalopram in the human serotonin transporter.R-citalopram functionally antagonises escitalopram in vivo and in vitro: evidence for kinetic interaction at the serotonin transporter.Effects of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal cortex of rats: role of 5-HT1A receptorsStereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs.Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters.Escitalopram: A New SSRI for the Treatment of Depression in Primary Care.Trends in the development of new antidepressants. Is there a light at the end of the tunnel?Metabolism of citalopram enantiomers in CYP2C19/CYP2D6 phenotyped panels of healthy SwedesTransfer of escitalopram and its metabolite demethylescitalopram into breastmilkPharmGKB summary: citalopram pharmacokinetics pathway.Efficacy and safety of generic escitalopram (Lexacure(®)) in patients with major depressive disorder: a 6-week multicenter, randomized, rater-blinded, escitalopram-comparative, non-inferiority study.A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer's disease patients with agitation.Drug treatment of depression in the 2000s: An overview of achievements in the last 10 years and future possibilities.Changes in antidepressant metabolism and dosing across pregnancy and early postpartumThe use of escitalopram beyond major depression: pharmacological aspects, efficacy and tolerability in anxiety disorders.Escitalopram for the treatment of major depression and anxiety disorders.Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram.Clinical pharmacology review of escitalopram for the treatment of depression.CYP2D6 genetic polymorphisms and their relevance for poisoning due to amfetamines, opioid analgesics and antidepressants.Newer antidepressants in the primary care setting.An emerging role for escitalopram in the treatment of obsessive-compulsive disorder.Prediction of clinical response based on pharmacokinetic/pharmacodynamic models of 5-hydroxytryptamine reuptake inhibitors in mice.
P2860
Q24594466-BA540C62-4099-4808-94F6-584B06D26D13Q24657515-1F247C4C-8E44-44D7-BF35-DC7F114B9E2FQ28258698-05CBDBAB-FBD0-47E0-8E58-48DDDB4C50C2Q28363020-BDB6543B-0B44-4D10-AA1A-7D79464F2E2BQ28583883-DA7EA090-B81D-4FA1-9B1D-F50C93198094Q30468153-298CF7CA-0719-45EF-93E0-15FBF4F49034Q33623987-253A7BDB-F8A0-4D1C-A255-209986E3BB7FQ33677537-6DFC3D57-9526-47CE-9F09-65B9A5C7B7B4Q33928322-F09676B1-AD6F-4395-A678-9AB470EA9A87Q34016393-0376433F-C77E-4C63-91DE-5EE400B64F92Q34019331-4E8E69CD-94C0-4D55-9160-86FB86975ECFQ34065310-A3E7D38E-72BF-4356-9FA0-06A6155E4732Q34072466-5129AE2F-85E7-4C2B-A0A2-B187D92193D1Q34180357-9BF2FEB3-1C6B-4841-A089-582C8EC73FC8Q34240991-C4AF15B4-7814-448E-9E49-B76F0C224344Q34546245-C0B7A41B-1F9F-4A87-834B-BC7BE5471B6FQ34974884-B2A9CB34-B9F4-4636-8F01-796802E56AB0Q34982628-8DE6A6D1-D210-4C07-97A2-3D5F82EE0C44Q35011459-C25C2286-D00A-4D42-B3CF-9D92E88468AEQ35047103-A8C0F9BF-AD73-45FC-810E-B9107B03F48AQ35047176-5B26C26C-7F5F-4F2E-9D57-B801B7F2441BQ35054997-19F9A66A-C2BA-46A8-810E-4F98190FAD6CQ35123142-13D5ECC9-3F14-4645-9073-F2636D5AE740Q35160849-5C8F2AC3-8CFC-419B-B680-7A2CEBACD23CQ35743638-358F836D-D8D5-46A8-8E9D-92BC1AAEFBCEQ35825761-5F420E19-9709-42F8-9224-5DEDD0B9B38EQ35827773-1EEA1B4B-CA94-45D3-9F58-684A256BA06CQ35952370-1AA90BAD-2690-4116-BEED-A8D6690A0307Q36160446-21A6D0E8-5CC6-491C-8D1D-C905D529DD67Q36484557-EC81C400-2299-4556-9C7B-17C01348A5CCQ36637666-14F54C08-8257-42B8-BE42-3F3ABCE84CA6Q36692162-900FD081-3A05-4A1D-AA31-74BAF7EC59B9Q36960563-AA3ACB56-A7F7-41B3-B9B3-69110809FD05Q37139768-B6315C51-9105-442D-8026-96E163D982BAQ38153098-39CA531F-535D-4092-924D-432735838116Q38167375-B75C76CB-FD3B-401F-9EA3-8D5F5E0FFBBAQ38496627-562141EE-6BA9-4164-860C-4C6E8D1235B0Q40407621-18E8EC1C-984F-485E-B4FC-1C2AE21FB216Q41981820-C3AC6887-B4AB-4D43-A40E-6474FE3ED8E0Q42284309-AB8D3A18-947A-4ABA-89AD-022987213AAF
P2860
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
description
1992 nî lūn-bûn
@nan
1992 թուականին հրատարակուած գիտական յօդուած
@hyw
1992 թվականին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@ast
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@en
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@nl
type
label
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@ast
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@en
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@nl
prefLabel
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@ast
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@en
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@nl
P2093
P356
P1476
The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer
@en
P2093
J Perregaard
K P Bøgesø
P2888
P304
P356
10.1007/BF01244820
P407
P577
1992-01-01T00:00:00Z